Compare FUNC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUNC | CABA |
|---|---|---|
| Founded | 1900 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.8M | 200.2M |
| IPO Year | N/A | 2019 |
| Metric | FUNC | CABA |
|---|---|---|
| Price | $38.62 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 16.7K | ★ 3.0M |
| Earning Date | 10-20-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 56.67 | N/A |
| EPS | ★ 3.84 | N/A |
| Revenue | ★ $83,662,000.00 | N/A |
| Revenue This Year | $16.22 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | $9.94 | ★ N/A |
| Revenue Growth | ★ 17.79 | N/A |
| 52 Week Low | $24.66 | $0.99 |
| 52 Week High | $42.50 | $5.46 |
| Indicator | FUNC | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 52.01 |
| Support Level | $37.74 | $2.01 |
| Resistance Level | $38.69 | $2.69 |
| Average True Range (ATR) | 0.73 | 0.21 |
| MACD | 0.26 | 0.02 |
| Stochastic Oscillator | 95.72 | 71.32 |
First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.